Virtual event takes place December 1, 2022
ROCHESTER, Mich., Oct. 20, 2022 (GLOBE NEWSWIRE) — OptimizeRx Corp (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced the third annual Innovate4Outcomes® event co-sponsored by Melinta Therapeutics. This virtual event will take place on December 1, 2022. The sponsors are inviting participation from healthcare providers, pharmaceutical and medical technology manufacturers, healthcare marketing and advertising agencies, and others in the life sciences industry.
Innovate4Outcomes is a design-thinking, half-day event that brings together those interested in cross-industry collaboration to brainstorm potential pathways to reduce the threat of systemic healthcare challenges in the US. This year’s challenge has been identified by the World Health Organization as one of the ten most pressing current global health challenges: Antimicrobial Resistance (AMR). AMR has many facets which are aggravated by siloed care delivery pathways and social issues, among them treatment resistance, challenges in developing new therapies, provider education and health equity. A recent study published in The Lancet estimated that there were approximately 5 million global deaths associated with bacterial AMR in 2019, in addition to numerous other harmful impacts on human health and longevity.
“We’re delighted to co-sponsor this event with OptimizeRx,” said Matthew Balogh, Head of Digital Marketing, Melinta Therapeutics. “AMR is a far-reaching health concern that will require new thinking to address, and Innnovate4Outcomes allows the healthcare community to come together and leverage their own varied backgrounds and experiences to add to the conversation.”
On the day of the event, registrants will be divided into teams and will learn which of three systemic healthcare challenges related to AMR they will be assigned. Six teams, two for each challenge, will work together to envision future approaches to this significant health concern. Teams will then pitch their ideas to a panel of judges, and OptimizeRx will invest in the winning concept with the aim of creating a business case for further development.
“Our annual design-thinking in healthcare event, Innovate4Outcomes, speaks to the visionary approach we take every day in working with our industry colleagues to improve therapy awareness, access, and adherence for patients,” said Maria Cipicchio, SVP of Marketing and Communications, OptimizeRx. “Global health challenges like AMR take creative approaches to problem-solving, and we hold this annual event to envision a better future state of healthcare. We’re delighted to be in a position this year to allow the opportunity to extend ongoing support to investigate whether we can bring the winning idea to life.”
The event is free, and invitations are required for event access. Visit this link to request an invitation.
OptimizeRx provides best-in-class health technology that enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. Connecting over 60% of U.S. healthcare providers and millions of their patients through the most intelligent technology platform embedded within a proprietary digital point-of-care network, OptimizeRx helps patients start and stay on their medications.
For more information, follow the Company on Twitter, LinkedIn, or visit www.optimizerx.com.
About Melinta Therapeutics
Melinta Therapeutics, LLC provides innovative therapies to people impacted by acute and life-threatening illnesses. Our portfolio currently includes six commercial-stage products: Baxdela® (delafloxacin), Kimyrsa® (oritavancin), Minocin® (minocycline) for Injection, Orbactiv® (oritavancin), TOPROL-XL® (metoprolol succinate) and Vabomere® (meropenem and vaborbactam). With an unsurpassed commitment to providers and the patients they serve, we work to ensure that all people who need our therapies can receive them. We focus our expanding portfolio on serving patients with an unmet need because that’s how we make the most meaningful impact. At Melinta, we’re visionaries dedicated to innovation while staying grounded in what matters most: patients. For additional information, including product and respective important safety information, please visit our website.
Important Cautions Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s growth, business plans and future performance. These forward-looking statements are based on the Company’s current expectations and assumptions regarding the Company’s business, the economy, and other future conditions. The Company disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except as required by applicable law. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other risks summarized in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, its subsequent Quarterly Reports on Form 10-Q, and its other filings with the Securities and Exchange Commission.
Andy D’Silva, SVP Corporate Finance
Media Relations Contact
Kimberley Sirk, Media Relations Manager
Investor Relations Contact
LifeSci Advisors, LLC
The Gaithersburg vaccine maker has earned the Centers for Disease Control and Prevention’s recommendation to make its protein-based shot available as a booster to adults in the U.S., the last hurdle required before people can use it beyond a primary series. The CDC said late Wednesday that its director, Dr. Rochelle Walensky, greenlit the decision — which gives initially vaccinated adults the choice to get Novavax’s jab as a booster instead of the updated Omicron-specific shots from Pfizer-BioNTech or Moderna. Novavax’s vaccine instead uses a decades-old technology found in vaccines for viruses such as flu and whooping cough, which the company is hoping will spur demand from people unable to, or who choose not to, receive the newer mRNA vaccines.
We’re in a volatile bear market right now, and key riddle investors need to answer is, which stocks are going to bring the best returns, even in today’s uncertain conditions. One market segment that can’t be ignored is the low-cost penny stocks. These equities, typically priced under $5 per share, offer the best combination of risk and reward: a minimal cost of entry, and frequently triple-digit upside potential. Going beyond the argument that you get more for your money, even minor price apprec
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments.
If the Centers for Disease Control and Prevention follows the guidance of its advisory panel, the shots would be part of the agency’s lists of recommended inoculations for adults and children.
Food and Drug Administration (FDA) authorization for a product typically delivers a nice stock price boost for the affected company. This, however, wasn't the case with vaccine specialist Novavax (NASDAQ: NVAX) on Hump Day, as the latest FDA green light had the opposite effect, driving the shares down by almost 4% on the day. The FDA has granted emergency use authorization (EUA) for Novavax's booster coronavirus shot, an adjuvanted version of its NVX-CoV2373.
What happened Shares of Moderna (NASDAQ: MRNA) fell 7.9% on Wednesday after health regulators authorized Novavax's (NASDAQ: NVAX) COVID-19 vaccine, Adjuvanted, as a booster for adults. So what The Centers for Disease Control and Prevention (CDC) will allow Novavax's vaccine to be used as a first booster shot for people aged 18 and older who would rather take it than initial boosters offered by Moderna and Pfizer (NYSE: PFE).
The WHO found that omicron subvariant XBB, which may be even more resistant to antibodies than other variants, spread to more countries in the week ending Oct. 16 from the previous week.
RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.
Some epidemiologists are predicting a rise in cases of COVID starting soon with Halloween & winter setting in. We share latest on why and what to do.
Shares of Biogen (NASDAQ: BIIB) have been volatile in the past few years, largely hinging on success of the company's Alzheimer's treatments. Sales in recent years have been declining, and the loss of patent protection for top-selling multiple sclerosis treatment Tecfidera is only exacerbating those concerns. What will the company's business look like over the next five years, and is it promising enough for investors to buy shares of Biogen today?
By his fourth week waiting for help in the emergency room, Zachary Chafos's skin had turned pale white from lack of sun. His mother, Cheryl Chafos, bathed her autistic teenage son daily in the ER's shower, trying to scrub the sickly pallor off him. His father, Tim Chafos, held the 18-year-old's hand, trying to soothe his son's pain and confusion over what was happening.Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. They'd brought Za
SNC-Lavalin (TSX: SNC), a fully integrated professional services and project management company with offices around the world, today announces it has been awarded a series of three contracts with the Société Québécoise des infrastructures (Quebec Infrastructure Corporation), to strengthen hospital infrastructure at sites across Quebec. Major expansion and redevelopment work will take place at the Hospital of Chicoutimi, Sept-Îles Hospital, and the Charles Le Moyne Hospital. A central focus of th
The guest model told the magazine that she was unhappy with her body before her breast cancer diagnosis, but that she gained perspective after getting sick.
A newly identified colon cancer gene may drive the disease by making the environment in the vicinity of tumors more hospitable to them, researchers say.
Increasing expenses amid inflation is shrinking margins for the Zacks Medical-Hospital industry players. However, HCA Healthcare (HCA), Acadia Healthcare (ACHC), Universal Health (UHS) and Tenet Healthcare (THC) are poised to win big with recovering patient volumes.
A national shortage of Adderall has left patients who rely on the pills for attention-deficit/hyperactivity disorder scrambling to find alternative treatments and uncertain whether they will be able to refill their medication. The Food and Drug Administration announced the shortage last week, saying that one of the largest producers is experiencing "intermittent manufacturing delays" and that other makers cannot keep up with demand.Subscribe to The Post Most newsletter for the most important and
Gwyneth Paltrow is all about living a healthy, balanced life. The Goop founder spoke with Access Hollywood’s Zuri Hall and shared about her collection with Copper Fit, her love of wellness, and more. The 50-year-old also opened up about her fascination with wellness, saying her interest all began when her father Bruce Paltrow, was diagnosed with cancer.
Here’s a comprehensive checklist for your Medicare coverage—take the time to review what you have, and what you’ll need next year
NEW YORK (Reuters) -Pfizer Inc expects to roughly quadruple the price of its COVID-19 vaccine to about $110 to $130 per dose after the United States government's current purchase program expires, Pfizer executive Angela Lukin said on Thursday. Lukin said she expects the vaccine – currently provided for free to all by the government – will be made available at no cost to people who have private insurance or government paid insurance. Reuters earlier on Thursday reported that Wall Street was expecting such price hikes due to weak demand for COVID vaccines, which meant vaccine makers would need to hike prices to meet revenue forecasts for 2023 and beyond.
Professional golfer Luis Vega woke up suddenly unable to move his legs. Doctors performed emergency spinal surgery and diagnosed him with a "remarkably rare" condition.